目的 观察强化心肌病治疗对尿毒症性心肌病患者N末端脑钠肽前体(NT-proBNP)、心脏腔室的影响.方法 将100例尿毒症性心肌病患者随机分成强化治疗组及常规治疗组各50例,常规治疗组常规血液透析治疗,强化治疗组在血液透析基础上强化心肌病药物治疗,治疗1、3、6、12个月后检测2组患者NT-proBNP、心脏腔室及射血分数变化.结果 强化治疗组与常规治疗组同期对比心功能明显改善,NT-proBNP数值明显下降(P＜0.05),心脏各腔室回缩率及心脏射血分数提高率均明显改善(P＜0.05),强化治疗组心功能总有效率显著高于常规治疗组(88.0% vs 72.7%,P<0.05),且无明显不良反应.结论 尿毒症性心肌病患者强化心肌病药物治疗可明显改善患者心功能,提高生活质量,延长生命.%Objective To investigate the clinical effect of strengthen cardiomyopathy therapy on uremic cardiomyopa-thy with the change of the NT-proBNP and cardiac chamber. Methods 100 patients of uremic cardiomyopathy were divided into strengthen treatment group and conventional treatment group randomly, each group had 50 patients. In conventional treatment group, the hemodialysis was applied, and in strengthen treatment group, the drug therapy was applied on the basis of he-modialysis. The expression of NT-proBNP, the change of cardiac chamber and ejection fraction were detected and compared in both two groups. Results The result showed that the cardiac function was improved obviously in strengthen treatment group than that of in conventional treatment group, with the decline of the expression of NT-proBNP significantly( P <0. 05 ). The cardiac chamber size contraction and cardiac ejection fraction increase rate were improved significantly in strengthen treatment group than those of conventional treatment group( P < 0.05 ). The total effective rate was higher in strengthen treatment group ( 88.0% ) than that of conventional treatment group ( 72.7% , P <0.05 ). And no obvious adverse reactions was observed in both two groups. Conclusion It proved that adding the neuroendocrine medicine to the therapy of the patients with uremic myocardiopathy could improve the patients'cardiac function obviously, enhance the life quality and increase the life span.
展开▼
